TLC denies rumours of CEO resignation:
This article was originally published in Clinica
Laser surgery services company TLC has denied rumours that its president and CEO, Elias Vamvakas, has already, or intends to resign. Mr Vamvakas is also one the company's largest individual shareholders. The Bethesda, Maryland-based company issued the statement following speculation after recent increased trading in its shares. TLC believes a similar false rumour on the Internet concerning the CEO of one of its competitors may have fuelled the suggestion. No senior management members have resigned, or intend to, and the company is unable to explain the market activity in its shares.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.